Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asahi Ito

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
International Journal of Hematology|May 24, 2019
Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myelomaTakashi Yoshida, Masaki Ri, Haruna Fujinami, et al.
Cancer Science|February 16, 2020
Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myelomaTakuto Tachita, Shiori Kinoshita, Masaki Ri, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 5, 2013
Autologous Tax-specific CTL therapy in a primary adult T cell leukemia/lymphoma cell-bearing NOD/Shi-scid, IL-2Rγnull mouse modelAyako Masaki, Takashi Ishida, Susumu Suzuki, et al.
Hematological Oncology|September 17, 2020
Clinical significance of tryptophan catabolism in follicular lymphomaAyako Masaki, Takashi Ishida, Yasuhiro Maeda, et al.
Annals of Hematology|November 12, 2015
Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysisTomotaka Suzuki, Shigeru Kusumoto, Taro Yamashita, et al.
International Journal of Hematology|December 31, 2015
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myelomaHaruhito Totani, Masaki Ri, Chie Kato, et al.
Oncotarget|March 9, 2018
Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunitsTakashi Yoshida, Masaki Ri, Takashi Kanamori, et al.
British Journal of Haematology|August 18, 2021
Clinical significance of TP53 mutations in adult T-cell leukemia/lymphomaYuma Sakamoto, Takashi Ishida, Ayako Masaki, et al.
Haematologica|August 5, 2018
Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphomaShiori Kinoshita, Takashi Ishida, Asahi Ito, et al.
Cancer Science|September 6, 2008
Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myelomaHiroki Yano, Satoshi Kayukawa, Shinsuke Iida, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
International Journal of Hematology|May 24, 2019
Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myelomaTakashi Yoshida, Masaki Ri, Haruna Fujinami, et al.
Cancer Science|February 16, 2020
Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myelomaTakuto Tachita, Shiori Kinoshita, Masaki Ri, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 5, 2013
Autologous Tax-specific CTL therapy in a primary adult T cell leukemia/lymphoma cell-bearing NOD/Shi-scid, IL-2Rγnull mouse modelAyako Masaki, Takashi Ishida, Susumu Suzuki, et al.
Hematological Oncology|September 17, 2020
Clinical significance of tryptophan catabolism in follicular lymphomaAyako Masaki, Takashi Ishida, Yasuhiro Maeda, et al.
Annals of Hematology|November 12, 2015
Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysisTomotaka Suzuki, Shigeru Kusumoto, Taro Yamashita, et al.
International Journal of Hematology|December 31, 2015
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myelomaHaruhito Totani, Masaki Ri, Chie Kato, et al.
Oncotarget|March 9, 2018
Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunitsTakashi Yoshida, Masaki Ri, Takashi Kanamori, et al.
British Journal of Haematology|August 18, 2021
Clinical significance of TP53 mutations in adult T-cell leukemia/lymphomaYuma Sakamoto, Takashi Ishida, Ayako Masaki, et al.
Haematologica|August 5, 2018
Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphomaShiori Kinoshita, Takashi Ishida, Asahi Ito, et al.
Cancer Science|September 6, 2008
Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myelomaHiroki Yano, Satoshi Kayukawa, Shinsuke Iida, et al.
Pageof 7